FDA approves expanded use of Opdivo in advanced lung cancer
(HealthDay)—The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with advanced non-small-cell lung cancer (NSCLC) whose disease progressed despite platinum-based chemotherapy.
Oct 12, 2015
0
16